The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status

Ricky M. Trigg, Liam C. Lee, Nina Prokoph, Leila Jahangiri, C. Patrick Reynolds, G. A. Amos Burke, Nicola A. Probst, Miaojun Han, Jamie D. Matthews, Hong Kai Lim, Eleanor Manners, Sonia Martinez, Joaquin Pastor, Carmen Blanco-Aparicio, Olaf Merkel, Ines Garces de los Fayos Alonso, Petra Kodajova, Simone Tangermann, Sandra Högler, Ji LuoLukas Kenner, Suzanne D. Turner*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    29 Citations (SciVal)
    Original languageEnglish
    Article number5428
    JournalNature Communications
    Volume10
    Issue number1
    DOIs
    Publication statusPublished (VoR) - 1 Dec 2019

    Fingerprint

    Dive into the research topics of 'The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status'. Together they form a unique fingerprint.

    Cite this